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Abstract 
Background: An ultrasensitive malaria rapid diagnostic test (RDT) was recently developed for the improved detec-
tion of low-density Plasmodium falciparum infections. This study aimed to compare the diagnostic performance of the 
PfHRP2-based Abbott Malaria Ag P. falciparum ultrasensitive RDT (uRDT) to that of the conventional SD-Bioline Malaria 
Ag P. falciparum RDT (cRDT) when performed under field conditions.
Methods: Finger-prick blood samples were collected from adults and children in two cross-sectional surveys in May 
of 2017 in southern Mozambique. Using real-time quantitative PCR (RT-qPCR) as the reference method, the age-spe-
cific diagnostic performance indicators of the cRDT and uRDT were compared. The presence of histidine-rich protein 
2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH) antigens was evaluated in a subset from dried blood spots 
by a quantitative antigen assay. pfhrp2 and pfhrp3 gene deletions were assessed in samples positive by RT-qPCR and 
negative by both RDTs.
Results: Among the 4,396 participants with complete test results, the sensitivity of uRDTs (68.2; 95% CI 60.8 to 74.9) 
was marginally better than that of cRDTs (61.5; 95% CI 53.9 to 68.6) (p-value = 0.004), while the specificities were simi-
lar (uRDT: 99.0 [95% CI 98.6 to 99.2], cRDT: 99.2 [95% CI 98.9 to 99.4], p-value = 0.02). While the performance of both 
RDTs was lowest in ≥ 15-year-olds, driven by the higher prevalence of low parasite density infections in this group, the 
sensitivity of uRDTs was significantly higher in this age group (54.9, 95% CI 40.3 to 68.9) compared to the sensitivity 
of cRDTs (39.2, 95% CI 25.8 to 53.9) (p-value = 0.008). Both RDTs detected P. falciparum infections at similar geometric 
mean parasite densities (112.9  parasites/μL for uRDTs and 145.5 parasites/μL for cRDTs). The presence of HRP2 antigen 
was similar among false positive (FP) samples of both tests (80.5% among uRDT-FPs and 84.4% among cRDT-FPs). Only 
one false negative sample was detected with a partial pfhrp2 deletion.
Conclusion: This study showed that the uRDTs developed by Abbott do not substantially outperform SD-Bioline Pf 
malaria RDTs in the community and are still not comparable to molecular methods to detect P. falciparum infections in 
this study setting.
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Background
Despite control and elimination efforts worldwide, 
malaria remains a major global health problem. This 
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accounted for an estimated 228 million cases and 405,000 
deaths in 2018, most of them circumscribed to sub-Saha-
ran Africa and concentrated in the under-five years of age 
and pregnant populations [1]. The World Health Organi-
zation (WHO) Global Technical Strategy for malaria 
(2016–2030) promotes that all malaria-endemic coun-
tries should ensure universal access to malaria preven-
tion, diagnosis and treatment while transforming their 
malaria surveillance systems into core interventions [2]. 
Therefore, the accurate detection of malaria infections 
is essential to provide high-quality case management to 
all malaria infected patients, as well as to inform surveil-
lance systems to allow monitoring progress and guiding 
where to target interventions.
Microscopic visualization of peripheral blood smears 
has traditionally been the most commonly used method 
to confirm the presence of Plasmodium parasites, but 
this changed with the appearance of malaria rapid diag-
nostic tests (RDTs) in the early 2000s [1]. Malaria RDTs 
are a simple, rapid, cheap and field-deployable way to 
accurately identify a malaria infection at the point of care, 
being especially useful in low-resource and rural set-
tings without access to laboratory facilities. Their use has 
sharply increased in the last years and an estimated 412 
million tests were sold globally in 2018 [1]. These RDTs 
are immunochromatographic lateral flow devices capa-
ble of detecting one or more specific Plasmodium pro-
teins in a small volume of blood (typically a single drop, 
which can be obtained by finger-prick). There are various 
commercially available tests that detect different para-
site molecules produced during the erythrocytic cycle, 
namely the Plasmodium falciparum (Pf) histidine-rich 
protein 2 (HRP2), the Plasmodium genus or species-spe-
cific lactate dehydrogenase (pLDH) and the Plasmodium 
genus or species-specific aldolase [3].
HRP2-based RDTs are the most widely used across 
malaria-endemic Africa [1]. However, their perfor-
mance is affected by a series of factors [4, 5]. False posi-
tive results can be due to: (i) HRP2 persistence in the 
bloodstream after infection clearance (and thus, are not 
technically false positives), which has been reported to 
last for several weeks (up to 4–6 weeks) after treatment 
[6, 7]; and to a lesser extent (ii) presence of autoantibod-
ies and other infections [8]. False negative results can be 
caused by: (i) parasite pfhrp2 and pfhrp3 gene deletions, 
which cause absence of PfHRP2 expression and have 
been increasingly observed throughout Latin America 
and Africa [9, 10]; (ii) very high parasite densities (i.e. 
prozone effect) [11]; as well as (iii) low-density parasite 
infections under the RDT detection threshold capac-
ity. Given that regular RDTs have a detection threshold 
of ~ 100  parasites/μL (0.002% parasitaemia) [12], this is 
of particular relevance in malaria endemic areas where a 
large proportion of malaria infected individuals, usually 
afebrile, have parasite densities below the RDTs threshold 
of detection [13–15]. Thus, their infections remain unde-
tected and hence uncleared for longer periods of time, 
representing a potential—yet poorly understood—reser-
voir of infection in endemic areas [16]. Missing them may 
hinder efforts to reduce transmission and leads to inac-
curate burden estimations.
Polymerase chain reaction (PCR) assays have great 
analytical performance and can detect very low parasi-
taemias (as low as < 1 parasites/μL) [17, 18], but they are 
impractical for field use and their high cost keep them 
inaccessible in malaria endemic settings. The renewed 
interest in malaria elimination in the past decade has 
instigated discussions around the need for more sensi-
tive malaria RDTs that can detect lower-level parasite 
densities than conventional RDTs (cRDTs) in the com-
munity, to be used mainly in efforts aiming to interrupt 
transmission. In this context, the Abbott (previously 
Alere™) Malaria Ag P. falciparum ultrasensitive RDT 
(uRDT) was developed. This is an HRP2-based test that 
has a tenfold lower limit of detection in vitro (40–125 pg/
ml of HRP2) when compared to the commonly used SD-
Bioline Malaria Ag P. falciparum RDT (800–1000 pg/ml) 
[19] and was prequalified by the WHO in 2019. It has 
the same immunochromatographic cassette platform, 
requires the same blood volume (5μL) and takes only 
5  min longer (20 instead of 15) to obtain a result com-
pared to the SD-Bioline RDT (cRDT), but has worse stor-
age stability (30 °C versus 40 °C) [19].
Previous studies have evaluated the diagnostic perfor-
mance of uRTDs in different transmission settings, popu-
lations and use-case scenarios, with the aim of informing 
malaria elimination strategies, or improving case man-
agement in the general population and among pregnant 
women. Several studies evaluated uRDT performance in 
cross-sectional surveys using stored frozen-thawed blood 
samples or running tests under laboratory conditions. 
These studies have shown a great variation in uRDT sen-
sitivities when compared to PCR (from 27 to 84) [20–23], 
but results are not comparable to those obtained under 
field conditions. Assessment of the performance of the 
uRDTs in cross-sectional surveys conducted in The 
Gambia, Myanmar and Cambodia indicate that uRDTs 
outperforms cRDTs in different magnitudes when used 
to test individuals in the community. uRDT sensitivity 
estimates also varied across studies (from 35 to 60, when 
a PCR assay was considered the gold-standard), but all 
studies consistently reported that uRDTs miss a high 
percentage of infections detected by molecular methods 
[23–26]. Studies evaluating the potential role of uRDTs 
in case management found no differences in the perfor-
mance of uRDTs and cRDTs for clinical malaria diagnosis 
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among non-pregnant patients [27]. Finally, a similar or 
higher performance of uRDTs compared to cRDTs has 
been reported in pregnant women when tested using ret-
rospectively collected peripheral or placental blood sam-
ples [28–30].
Mozambique is one of the countries with the highest 
malaria burden worldwide [1]. cRDTs were introduced 
in 2007 and they were rolled out at the national level in 
2010. PfHRP2-based RDTs are used for malaria diagno-
sis in the country, as P. falciparum is the major cause of 
malaria and there is a low prevalence of parasites with 
pfhrp2 and pfhrp3 gene deletions [31, 32]. In this study, 
the diagnostic performance of the PfHRP2-based Abbott 
Malaria Ag P. falciparum uRDT and the SD-Bioline 
Malaria Ag P. falciparum cRDT were evaluated against 
RT-qPCR in children and adults who participated in two 
cross-sectional studies in the districts of Manhiça and 
Magude in Maputo province, southern Mozambique. The 
parasite density distributions of the detected infections 
were explored, and their performance compared, based 




The districts of Magude and Manhiça are located in 
Maputo province, southern Mozambique (Fig. 1). The dis-
trict of Manhiça is a rural district of ~ 2300  km2 located 
80 km north of Maputo City, the capital of Mozambique. 
Manhiça district is divided in six administrative posts: 
Maluana, Manhiça, Calanga, 3 de Fevereiro, Ilha Josina 
Machel and Xinavane. According to the national 2017 
census, it has a population of ~ 208,000 inhabitants and 
~ 50,000 households [33]. The district of Magude borders 
with Manhiça on the north-west and is the northernmost 
district of Maputo province. It is divided in five adminis-
trative posts: Magude Sede, Motaze, Panjane, Mahele and 
Mapulanguene. According to the national 2017 census, 
Fig. 1 Map of Magude district, Manhiça district and Xinavane administrative post (Manhiça district); all located in Maputo Province, the 
southernmost province of Mozambique
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it has a population of ~ 64,000 inhabitants and ~ 15,000 
households and it has ~ 7000  km2 [33]. The Manhiça 
Health Research Center (CISM) expanded its presence to 
Magude in 2014, in the context of a malaria elimination 
feasibility project planned for the district for the period 
of 2015–2019 [34].
Plasmodium falciparum malaria transmission is peren-
nial in the area but with a peak between November and 
April, coinciding with the rainy season. The incidence 
of passively reported malaria cases during the transmis-
sion season of the study (July 2016 to June 2017) was 
186 cases per 1000 in Manhiça and 75 cases per 1000 in 
Magude [35] Anopheles funestus is the most abundant 
vector responsible for the majority of transmission, fol-
lowed by Anopheles arabiensis [36, 37]. According to 
national case management guidance, all febrile patients 
are tested for malaria through PfHRP2-based cRDTs and 
uncomplicated malaria cases are offered treatment with 
artemether–lumefantrine (AL), the first-line treatment 
in Mozambique. Prior to this study, vector control meas-
ures in both districts consisted of routine long-lasting 
insecticidal net (LLIN) distributions to pregnant women 
attending the ANCs and children attending routine 
immunization services, as well as mass LLIN campaigns. 
Indoor residual spraying (IRS) has also been conducted 
in both districts through district-wide campaigns or 
focalized to the highest burden areas.
Study design
Two age stratified cross-sectional surveys with an over-
representation of children were conducted in the dis-
tricts of Magude and Manhiça at the end of the malaria 
transmission season, in May 2017. The cross-sectional 
survey conducted in Manhiça covered the original study 
area of the demographic surveillance system (DSS) estab-
lished by CISM in Manhiça, which includes the entire 
district except for the administrative posts of Xinavane 
and Calanga [38]. This survey was planned as part of the 
annual malaria surveys that started in 2010 to monitor 
malaria prevalence and vector control use in the district. 
The second survey covered the entire district of Magude 
and the administrative post of Xinavane (Manhiça), and 
it was aimed to measure infection prevalence after the 
first phase of a malaria elimination project being imple-
mented in the area since 2015 [34].
In both surveys, a simple random sample of partici-
pants was selected per age group from the census data-
bases available from Manhiça and Magude, collected and 
updated through the demographic surveillance platforms 
established in both districts [38, 39]. The age groups used 
to stratify the sample differed according to the district. 
In Manhiça, the age groups were: < 1, 1–< 2, 2–< 3, 3–< 4, 
4–< 5, 5–< 10, 10–< 20, 20–< 40, 40–< 60, > 60. In Magude 
district and Xinavane, the age groups were: < 6 months, 
6  months–< 2, 2–< 5, 5–< 15, > 15. The sample size for 
Manhiça and Xinavane was calculated to detect a preva-
lence of parasitaemia of 50% (conservative estimate with 
maximum imprecision) with a precision of ± 10% and 
a confidence coefficient of 95%. On the other hand, the 
sample size of the survey in Magude was calculated for 
each specific age group to detect a reduction in malaria 
prevalence of 90% with regards to that detected on the 
preceding year, with a power of 90% and a significance 
level of 5% [35].
Field and laboratory procedures
RDTs were performed under field-conditions. Partici-
pants’ fingers were disinfected and pricked by trained 
workers using the alcohol swabs and lancets provided by 
the manufacturer in the RDT kits. Approximately 5  μL of 
blood were collected using the manufacturer’s specimen 
collection inverted cups for the assessment of malaria 
infection with SD-Bioline RDT and Abbott RDT. Results 
were recorded for both tests after approximately 20 min. 
Individuals with a confirmed infection by either test 
were treated with AL (Coartem®) according to national 
guidelines.
A volume of approximately 30  μL of finger-pricked 
blood was collected using the specimen collection 
inverted cups provided in the RDT kits for the deter-
mination of parasitaemia on two thick (~ 10  μL each) 
and thin (~ 5  μL each) blood slides. Smears were air-
dried, stained with Giemsa and examined using a light 
microscope fitted with a 100 × oil immersion lens and a 
10 × eyepiece to quantify parasitaemia in CISM’s labo-
ratory. Slides were read twice by two different qualified 
microscopists using the Lambaréné method [40] A third 
reading was performed by an additional microscopist in 
the case of discordant results. If the third reading was 
positive, the sample was considered positive. Samples 
with a negative third reading were considered negative.
Two Whatman 903™ filter papers with two 50  μL 
blood spots were also collected. During the field activi-
ties, filter papers and blood smears were placed in clean 
containers where the blood did not come into contact 
with other materials. Afterwards, they were wrapped in 
aluminum paper with silica gel and placed in − 20  °C. 
All filter papers and smears were labelled with a unique 
identification number for each study participant. If blood 
collection was challenging and only a small volume was 
obtained, RDTs and RT-PCR were prioritized over blood 
slides.
Real time quantitative PCR (RT-qPCR) analyses were 
conducted in the laboratory at CISM (Manhiça, Mozam-
bique), with an estimated limit of detection of about 
2–5 parasites/μL [41]. DNA was extracted from half of a 
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50  µL dried blood drop on Whatman 903™ filter paper 
by using a QIAamp DNA Mini kit (250) from QIAGEN, 
according to the manufacturer’s instructions and eluted 
in 100  μL of elution buffer. The ABI PRISM 7500 HT 
Real-Time System (Applied Biosystems) was used to 
amplify purified parasite DNA templates, using a previ-
ously described method that targets the P. falciparum 
18S rRNA [41, 42] Parasitaemia in the clinical samples 
was quantified by extrapolation against the standard 
curve prepared from an in vitro culture of the 3D7 strain. 
Samples without amplification (Ct > 40) were considered 
negative. A negative control with no template DNA was 
run in all reactions.
The presence of HRP2 and two different pLDH (Pan 
specific pLDH [pLDH-Pan] and P. falciparum specific 
pLDH [pLDH–Pf]) antigens were estimated at PATH’s 
laboratories (Seattle, USA) through a Q-plex enzyme-
linked immunosorbent assay (ELISA) from a subset of 
223 samples comprised of samples positive by RT-qPCR 
and either cRDT or uRDT (N = 82), negative by all diag-
nostic forms (N = 45), as well as all samples positive by 
cRDT or uRDT but negative by RT-qPCR (N = 44) and 
samples positive by RT-qPCR but negative by both RDTs 
(N = 52). A small disc (6-mm) was punched out of each 
dried blood spot (DBS) and transferred to a well in a low-
binding V-bottom 96-well plate (Thermo Scientific) with 
calibrator diluent (Quansys Bioscience, Logan, UT). The 
plate was incubated overnight in 4 °C and shaken for 1 h 
at room temperature. The eluates were tested in two rep-
licates on Q-Plex Human Malaria Array (5-Plex, Quansys 
Biosciences) according to the manufacturer’s instructions 
[43], with one minor modification on the use of 4 × con-
centrated competitor. The positive and negative results 
were determined by the cutoff values which correspond 
to a lower 95% confidence bound of > 92% specificity from 
the receiver-operating characteristic (ROC) analysis per-
formed using PCR-confirmed clinical samples (Jang et al. 
2020; pers. commun.). Given that the HRP2-concentra-
tion levels in most samples were near the upper limit of 
quantification, parasite antigen data were used qualita-
tively to determine the presence or absence of antigens in 
relation to cRDT, uRDT and RT-qRTPCR results.
Finally, all samples that were positive by RT-qPCR 
but negative by both uRDT and cRDT (N = 55) were 
explored for parasite pfhrp2 and pfhrp3 gene deletions 
as described elsewhere [31]. First, to verify the presence 
of parasite DNA in the sample, a nested PCR targeting a 
single copy of the k13 gene was performed [44]. Secondly, 
samples found positive for k13 gene amplification were 
subjected to pfhrp2 and pfhrp3 PCRs, amplifying regions 
across exon 1 and 2 as well as only exon 2 [31]. Positive 
controls (laboratory-adapted culture lines 3D7 for both 
pfhrp2 and pfhrp3) and negative controls (HB3 for pfhrp3 
and DD2 for pfhrp2) were simultaneously amplified. PCR 
products were visualized using 2% agarose (Invitrogen) 
and a UV trans-illuminator. Lastly, pfhrp2 and pfhrp3 
deletions were considered if k13 gene PCR was positive 
but PCRs for pfhrp2 and pfhrp3 failed to amplify the 
respective gene fragments [31].
Data collection and management
Participants’ socio-demographic information, history of 
fever and malaria control and treatment measures used, 
as well as cRDT and uRDT results were collected during 
the field visits through an electronic questionnaire using 
the open access software REDCap [45, 46]. Results from 
all laboratory techniques (microscopy, RT-qPCR, ELISA, 
and pfhrp2 and pfhrp3 gene deletion assessments) were 
matched through the patients’ unique identifier to the 
field database.
Samples that did not have results for at least one of 
the main diagnostic tools (cRDT, uRDT and RT-qPCR) 
were excluded from this analysis. The distribution of 
characteristics was compared between individuals with 
(n = 3946) and without (n = 450) a microscopy diagnosis 
in order to evaluate the representativeness of the micros-
copy results. The characteristics of participants with a 
microscopy results were not significantly different from 
those without a microscopy result (all p > 0.05), and their 
information was, therefore, considered to be representa-
tive of the entire study sample.
Data analysis
Data were analysed using Stata/IC 16 (Stata Corp, Col-
lege Station, Texas, USA). Basic characteristics of partici-
pants were summarized using descriptive analyses. The 
pooled all-age prevalence of malaria measured by differ-
ent diagnostic methods was calculated separately for each 
study area (Manhiça, Xinavane and Magude), taking into 
account the different age weights as per the study design 
and for the complete study sample (prior to the exclusion 
of participants for the diagnostic performance analysis, 
as described above). The percentage of positive samples 
per diagnostic type (microscopy, cRDT, uRDT, and RT-
qPCR) was reported for the entire population and strati-
fied by age groups (< 5, 5–< 15 and ≥ 15 years old).
The diagnostic performance of cRDT and uRDT were 
assessed using RT-qPCR as the gold standard. An infec-
tion was considered true positive (TP) if it was both 
RT-qPCR-positive and RDT-positive, true negative (TN) 
if it was both RT-qPCR-negative and RDT-negative, and 
false negative (FN) if RDT-negative and RT-qPCR-posi-
tive. RDT-positive and RT-qPCR-negative results were 
considered (and will be referred to as such hereafter) as 
false positives (FP), understood as samples without an 
active infection, despite acknowledging that these results 
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may be detecting HRP2 antigenaemia from recently 
resolved infections, and thus may not technically be real 
false positives [20]. The association of age group and 
an RDT FP or FN result was explored calculating odds 
ratios (ORs) with logistic regression and estimating the 
strength of evidence with likelihood-ratio tests. The fol-
lowing performance indicators were calculated for cRDT 
and uRDT: sensitivity, specificity, positive predictive 
value (PPV), negative predictive value (NPV), positive 
likelihood ratio (LR+), negative likelihood ratio (LR-), 
diagnostic odds ratio (DOR) and area under the receiver 
operating characteristic curve (AUC) (Additional file  1: 
Table S1 presents the formulae used). Performance indi-
cators were also calculated separately for the age groups 
< 5, 5–< 15 and ≥ 15  years old. Exact McNemar’s tests 
were used to compare performance indicators between 
RDTs for the entire population and for same age groups. 
Chi-squared tests were used to compare performance 
indicators between age groups within an RDT type.
Geometric mean parasite densities (GMPDs) and 
minimal and maximal parasitaemias were calculated for 
different cRDT and uRDT outcomes, for the entire popu-
lation and stratified by age group. Parasite density distri-
butions of infections detected by RT-qPCR, uRDT, cRDT 
and microscopy were also described using smoothing 
Kernel density estimations. HRP2, pLDH-Pan, pLDH-Pf 
and pLDH-Pv antigenic positivity proportions were cal-
culated for the aforementioned subset of 223 samples 
stratified by RT-qPCR result. Chi-squared tests were used 
to compare antigen positivity between cRDT and uRDT. 
The proportion of infections with pfhrp2 and pfhrp3 gene 
deletions were calculated in the subset of both uRDT and 
cRDT FN samples.
As a secondary analysis, the performance of RDTs 
between febrile and afebrile individuals was also 
explored. Individuals were defined as febrile if their axil-
lary temperature was ≥ 37.5  °C when measured during 
the household visit or reported having had fever in the 
preceding 24 h, and afebrile if their axillary temperature 
was < 37.5  °C without reporting having had fever in the 
preceding 24  h. The presence of fever among individu-
als with RT-qPCR or RDT positive results was measured, 
and a comparison of the parasite density distributions 
between febrile and afebrile cases made. uRDT and 
cRDT sensitivity and specificity were calculated for both 
groups, and comparisons were made using Chi-squared 
tests and McNemar’s tests as previously explained. 
Finally, diagnostic results were explored among the preg-
nant women found during the surveys.
Ethical considerations
Study protocols were approved by CISM’s institutional 
ethics committee, Hospital Clínic of Barcelona’s Ethics 
Committee, and the Mozambican Ministry of Health 
National Bioethics Committee (reference numbers 143/
CNBS/17 and 90/CNBS/16). Prior to their initiation, 
the surveys and their respective designs were communi-
cated to the community leaders of Manhiça and Magude 
through the community outreach platforms established 
by CISM in both districts. Study results were shared 
with the community through the same channels. Written 
informed consent and oral assent (for 12 to 17 year-olds) 
was sought from all individuals, or parents/guardians if 
participants were younger than 18 years old.
Results
Study population characteristics
A total of 5342 participants were recruited from Man-
hiça (18.4%), Xinavane (9.2%) and Magude (72.4%) in 
May 2017. Of these, 946 samples (17.7%) were excluded 
from the analysis as they lacked results for one or both 
RDTs and/or RT-qPCR. Among the 4396 participants 
with complete test results, the median age was 4 years old 
(Interquartile range [IQR] = 3–10). Women accounted 
for 55.2% (2402/4353) of the study sample, among whom 
21 reported to be pregnant. Only 0.5% (19/4128) of par-
ticipants presented a body temperature ≥ 37.5  °C dur-
ing testing. However, 8.5% (371/4387) reported having a 
febrile episode in the preceding 24 h. Within the previous 
month, 14.6% (640/4394) reported having a febrile epi-
sode and 6.5% (284/4342) reported taking anti-malarials. 
Additional file  1: Table  S2 presents the detailed study 
population characteristics for the entire study sample and 
stratified by region.
Malaria prevalence
The all-age weighted malaria prevalence by cRDT was 
6.1% (95% confidence interval (CI) 4.2% to 8.7%) in Man-
hiça, 1.9% (95% CI 0.9% to 3.9%) in Xinavane and 2.6% 
(95% CI 2.0% to 3.4%) in Magude, while the weighted 
prevalence by uRDT in these same settings was 6.5% 
(95% CI 4.6% to 9.1%), 2.8% (95% CI 1.4% to 5.8%) and 
3.2% (95% CI 2.3% to 4.0%), respectively. The same indi-
cator measured by RT-qPCR was 7.9% (95% CI 5.5% to 
11.3%) in Manhiça, 6.1% (95% CI 3.4% to 10.8%) in Xina-
vane and 4.5% (95% CI 3.6% to 5.6%) in Magude.
Throughout all areas, there were 144 (3.3%) P. falcipa-
rum infections detected by cRDT, 166 (3.8%) by uRDT, 
and 179 (4.1%) by RT-qPCR (Table  1). Of the 3,946 
individuals for whom blood slide results were available, 
there were 47 (1.2%) infections detected by light micros-
copy (Fig.  2). When stratifying by age, the differences 
in the percentage of samples positive by each diagnos-
tic tool were intensified in the ≥ 15-year-old category 
(Fig. 2). In all age categories, microscopy detected a lower 
Page 7 of 15Galatas et al. Malar J          (2020) 19:451  
percentage of positive samples compared to the other 
diagnostic tools.
Performance of cRDT and uRDT compared to RT‑qPCR
Considering RT-qPCR as the gold standard, cRDT mis-
classified 34 RT-qPCR-negative samples as positive (FP) 
and 69 RT-qPCR-positive samples as negative (FN), while 
uRDT misclassified 44 RT-qPCR-negative samples as 
positive and 57 RT-qPCR-positive samples as negative 
(Table 1). Figure 3 presents a detailed breakdown of sam-
ples per combination of diagnostic results. Most FP were 
concentrated among the < 15  year-olds (31/34 in cRDTs 
and 40/44 in uRDTS). The odds of having a FN result 
by either RDT was significantly higher among the eldest 
and, contrarily, the odds of being FP was higher among 
the youngest (Table 2).
The sensitivity of uRDTs was slightly higher (68.2; 95% 
CI 60.8 to 74.9) than that of cRDTs (61.5; 95% CI 53.9 to 
68.6) (p-value = 0.004), while the specificity of both RDTs 
was very similar: 99.0 (95% CI 98.6 to 99.2) for uRDT 
and 99.2 (95% CI 98.9 to 99.4) for cRDT (p-value = 0.02). 
Table  3 presents the RDT-specific estimates of all per-
formance indicators calculated for the study sample and 
stratified by age. The age-specific sensitivities decreased 
significantly with increasing age within each RDT (uRDT 
p-value = 0.02, cRDT p-value < 0.001), but were simi-
lar when compared between RDTs for the < 5 and 5 to 
15-year-olds group. However, among > 15-year-olds, the 
sensitivity of uRDTs was substantially higher (54.9, 95% 
CI 40.3 to 68.9) than that of cRDTs (39.2, 95% CI 25.8 to 
53.9) (p-value = 0.008). Specificity was very high (≥ 98.5) 
across all age groups for both RDTs (Table 3).
Parasite densities by RT‑qPCR
The GMPD of infections detected by RT-qPCR was 77.5 
parasites/µL (95% CI 50.2 to 119.7) and decreased with 
increasing age. The GMPD was 112.9 parasites/µL (95% 
CI 65.3 to 195.0) among TP uRDT samples and 145.5 
parasites/µL (95% CI 82.0 to 258.0) among TP cRDT 
samples. FN samples by uRDT or cRDT had GMPDs 
of < 35 parasites/µL (Table 4).
The proportion of infections detected by uRDT, cRDT 
or microscopy increased with increasing parasite den-
sity (Fig.  4a). The proportion of infections detected by 
uRDT and cRDT were similar throughout the para-
site density spectrum, while the infections detected by 
microscopy tended to have higher parasite densities. Fig-
ure  4b depicts smoothed parasite density distributions 
of infections detected by RT-qPCR, uRDT, cRDT and 
microscopy.
Antigen detection by ELISA and gene deletions analysis
In order to better understand disagreements between 
diagnostic tools, 223 samples were analysed by Q-Plex 
ELISA for different parasite antigens (Table  5). 84.4% 
(27/32) FP samples by cRDT were HRP2 positive, com-
pared to 80.5% (33/41) of FP by uRDT (p-value = 0.67). 
The majority of the FP samples that were HRP2-positive 
were detected among children < 5-years-old (60.6% for 
uRDTs and 59.3% for cRDTs) and among the 5 to 15 age 
group (21.7% for uRDTs and 37.0% for cRDTs). HRP2 
was also detected in > 70% of samples positive by RT-
qPCR but negative by cRDT (73.0%) or by uRDT (70.4%) 
(Table 5).
DNA extraction for the identification of pfhrp2 and 
pfhrp3 gene deletions was successful in 32/55 FN samples 
by both uRDT and cRDT. Among these, a partial deletion 
Table 1 cRDT and uRDT diagnostic classification using RT-qPCR as the gold-standard
cRDT RT‑qPCR uRDT RT‑qPCR
+ve −ve Total +ve −ve Total
+ ve 110 34 144 +ve 122 44 166
− ve 69 4183 4252 −ve 57 4173 4230
Total 179 4217 4396 Total 179 4217 4396
Fig. 2 Percentage of infections detected per diagnostic 
tool, according to age group. All ages N = 4396 (microscopy 
N = 3946); < 5 years old N = 2373 (microscopy N = 2138); 5–< 15 years 
old N = 1159 (microscopy N = 1036); ≥ 15 years old N = 850 
(microscopy N = 757)
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of the exon 2 of the pfhrp2 gene was found in only one 
sample (3.1%) (Additional file 2: Figure S1). This sample 
was negative by both RDTs and by microscopy but had 
a parasite density of 227.3 parasites/μL measured by 
RT-qPCR. The antigens HRP2, pLDH-pan and pLDH-Pf 
were also detected in this sample by the antigen assay.
cRDT and uRDT performance among febrile and afebrile 
individuals and pregnant women
A secondary analysis was conducted to explore RDTs’ 
diagnostic performance among febrile and afebrile indi-
viduals in the community. An 8.7% (382/4393) of the 
study population had fever at the time of the study or 
reported a febrile episode during the preceding 24  h. 
Using RT-qPCR, malaria was detected in 13.9% (53/382) 
of these febrile individuals and in 3.1% of afebrile 
(126/4011) ones. Fever was detected or reported within 
preceding 24 h in 29.6% (53/179) of the individuals with 
a positive RT-qPCR, 33.7% (56/166) of individuals with a 
positive uRDT, and 35.4% (51/144) of individuals with a 
positive cRDT.
The GMPD of febrile participants was 346.3 parasites/
µL (95% CI 152.0 to 788.7) (n = 53) and 41.3 parasites/
µL (95% CI 25.6 to 66.5) (n = 126) for afebrile ones. Con-
sequently, the sensitivity of cRDTs was higher among 
febrile individuals (79.2; 95% CI 65.9 to 89.2) than 
among afebrile individuals (54.0; 95% CI44.9 to 62.9) 
(p-value = 0.002). Likewise, the sensitivity of uRDTs was 
higher among febrile individuals (84.9; 95% CI 72.4 to 
93.3) than among afebrile ones (61.1; 95% CI 52.0 to 69.7) 
(p-value = 0.002). Only the sensitivity among afebrile 
individuals varied significantly between RDTs.
Fig. 3 Venn diagrams of the distribution of positive results according to the diagnostic test used, in the entire population (a), in the < 5 year-olds 
(b), in the 5–15 year-olds (c) and in the ≥ 15 year-olds (d)
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Two infections were detected by RT-qPCR among the 
21 women who reported being pregnant in this study. 
One infection had a parasite density of 1904 parasites/
µL by RT-qPCR and was diagnosed by microscopy, cRDT 
and uRDT; and had detectable HRP2 antigenaemia. The 
other infection had a parasite density of 2.9 parasites/
µL by RT-qPCR, but was not detected by any other diag-
nostic tool despite having detectable HRP2. Neither pre-
sented with a fever during the survey nor reported having 
had a fever or taking anti-malarials in the preceding 
30 days.
Discussion
This study evaluated the performance of a recently devel-
oped ultrasensitive malaria RDT in field conditions 
among individuals in a malaria endemic community of 
southern Mozambique. The study showed that the sen-
sitivity of the Abbott Pf malaria uRDT (68.2) was mar-
ginally higher compared to the SD-Bioline Pf malaria 
cRDT (61.5), while specificities were very similar (99.0 
for uRDT vs. 99.2 for cRDT). This translated into very 
few differences in absolute numbers. The performance of 
both types of RDTs was affected by age in a study pop-
ulation exposed to malaria since a very young age [47]. 
In this context, both uRDTs and RDTs performed best 
in 5–< 15  year-olds, and worse in > 15  year olds. There 
was barely a difference between the parasite densities of 
infections detected by either test and both RDTs detected 
a similar proportion of HRP2-positive samples. 31.8% 
(57/179) and 38.5% (69/179) of infections were missed 
by uRDT and cRDT, respectively, which was not driven 
by pfhrp2 or pfhrp3 deletions, as only one FP sample was 
detected with a partial pfhrp2 deletion, in agreement 
with previous findings from Mozambique [31, 32].
Table 2 Logistic regression odd ratios of  having a  uRDT 
or cRDT false positive or negative result by age group
*  The N includes all positive samples (for the false-positive analysis) and all 
negative samples (for the false-negative analysis)
n/N* Odds Ratio Likelihood‑
ratio test
uRDT false positives
 < 5 23/66 1 0.05
 5–< 15 17/68 0.62 (0.30–1.32)
 ≥ 15 4/32 0.27 (0.08–0.86)
cRDT false positives
 < 5 19/63 1 0.19
 5–< 15 12/58 0.60 (0.26–1.39)
 ≥ 15 3/23 0.35 (0.09–1.31)
uRDT false negatives
 < 5 20/2306 1  < 0.001
 5–< 15 13/1091 1.38 (0.68–2.78)
 ≥ 15 23/818 3.31 (1.81–6.05)
cRDT false negatives
 < 5 19/2309 1  < 0.001
 5–< 15 18/1101 2.00 (1.05–3.83)
 ≥ 15 31/827 4.69 (2.64–8.36)
Table 3 cRDT and uRDT performance indicators using RT-qPCR as the gold-standard, overall and by age group
PPV Positive predictive value, NPV negative predictive value, LR+ positive likelihood ratio, LR− negative likelihood ratio, DOR diagnostic odds ratio, AUC area under the 
receiver operating characteristic curve
RDT type All ages (N = 4396) < 5 years old (N = 2373) 5–15 years old (N = 1159) ≥ 15 years old (N = 850)
Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) Estimate (95% CI)
Sensitivity cRDT 61.5 (53.9–68.6) 69.8 (57.0–80.8) 71.9 (59.2–82.4) 39.2 (25.8–53.9)
uRDT 68.2 (60.8–74.9) 68.3 (55.3–79.4) 79.7 (67.8–88.7) 54.9 (40.3–68.9)
Specificity cRDT 99.2 (98.9–99.4) 99.2 (98.7–99.5) 98.9 (98.1–99.4) 99.6 (98.9–99.9)
uRDT 99.0 (98.6–99.2) 99.0 (98.5–99.4) 98.5 (97.5–99.1) 99.5 (98.7–99.9)
PPV cRDT 76.4 (68.6–83.1) 69.8 (57.0–80.8) 79.3 (66.7–88.8) 87.0 (66.4–97.2)
uRDT 73.5 (66.1–80.0) 65.2 (52.4–76.5) 75.0 (63.0–84.7) 87.5 (71.0–96.5)
NPV cRDT 98.4 (98.0–98.7) 99.2 (98.7–99.5) 98.4 (97.4–99.0) 96.3 (94.7–97.4)
uRDT 98.7 (98.3–99.0) 99.1 (98.7–99.5) 98.8 (98.0–99.4) 97.2 (95.8–98.2)
LR + cRDT 76.2 (53.5–108.6) 84.9 (52.7–136.7) 65.6 (36.6–117.5) 104.4 (32.1–339.9)
uRDT 65.3 (47.9–89.1) 68.5 (44.1–106.4) 51.3 (31.5–83.6) 109.7 (40.0–300.7)
LR- cRDT 0.4 (0.3–0.5) 0.3 (0.2–0.4) 0.3 (0.2–0.4) 0.6 (0.5–0.8)
uRDT 0.3 (0.3–0.4) 0.3 (0.2–0.5) 0.2 (0.1–0.3) 0.5 (0.3–0.6)
DOR cRDT 196.1 (125.0–307.8) 279.1 (138.9–561.2) 230.6 (105.6–503.7) 171.2 (51.1–566.9)
uRDT 203.0 (131.9–312.5) 213.7 (109.7–416.4) 248.8 (115.3–536.9) 242.0 (81.2–714.0)
AUC cRDT 0.80 (0.77–0.84) 0.85 (0.79–0.90) 0.85 (0.80–0.91) 0.69 (0.63–0.76)
uRDT 0.84 (0.80–0.87) 0.84 (0.78–0.89) 0.89 (0.84–0.94) 0.77 (0.70–0.84)
Page 10 of 15Galatas et al. Malar J          (2020) 19:451 
Overall, these results raise the question of the added 
value of the uRDTs evaluated in this study, in Mozam-
bique. In fact, the utility of these uRDTs remains unclear, 
partly as a result of the emergent body of evidence in 
line with the performance outcomes presented here 
[21, 26, 27, 29]. In summary, three main use-cases have 
been proposed for this diagnostic tool: (1) To be used in 
malaria elimination contexts to more accurately measure 
prevalence or guide test-and-treat strategies to interrupt 
malaria transmission in the community, (2) for improved 
case management, and 3) to detect low-density infections 
among pregnant women. This study provides evidence to 
Table 4 Geometric mean parasite densities (GMPDs) by  RT-qPCR among  uRDT and  cRDT positive and  uRDT and  cRDT 
negative samples, according to age group
Result Method N RT‑qPCR GMPD 
(parasites/μL)
95% CI Min–Max (parasites/μL)
All ages Positive RT-qPCR 179 77.5 50.2–119.7 0.6–120,786.2
uRDT 122 112.9 65.3–195.0 0.6–120,786.2
cRDT 110 145.5 82.0–258.0 0.6–120,786.2
Negative uRDT 57 34.6 17.6–68.2 1.4–40,038.9
cRDT 69 28.4 15.5–51.9 0.9–40,038.9
< 5-year-olds Positive RT-qPCR 63 128.1 57.2–286.8 0.6–120,786.2
uRDT 43 187.2 69.1–507.2 0.6–120,786.2
cRDT 44 183.0 69.1–484.6 0.6–120,786.2
Negative uRDT 20 56.7 13.7–234.4 1.4–40,038.9
cRDT 19 56.2 12.5–252.1 1.4–40,038.9
5–< 15 year-olds Positive RT-qPCR 64 99.5 47.8–206.9 1.7–59,365.7
uRDT 51 99.5 42.3–233.9 1.7–59,365.7
cRDT 46 114.4 45.7–286.6 1.7–59,365.7
Negative uRDT 13 99.4 20.9–473.5 5.3–7235.0
cRDT 18 69.5 19.8–244.5 4.1–7235.0
 ≥ 15 year-olds Positive RT-qPCR 51 32.2 16.2–64.3 0.9–14,991.6
uRDT 28 65.2 22.5–189.6 0.9–14,991.6
cRDT 20 152.7 46.0–508.1 2.1–14,991.6
Negative uRDT 23 13.7 6.5–29.0 2.4–2311.7
cRDT 31 11.8 6.1–22.8 0.9–2311.7
Fig. 4 a Proportion of RT-qPCR positive infections detected by uRDT, RDT or microscopy per parasite density groups. Gray line: Number of RT-qPCR 
positives samples per parasite density groups. b Parasite density distributions of infections detected by microscopy, cRDT, uRDT and RT-qPCR
Page 11 of 15Galatas et al. Malar J          (2020) 19:451  
inform the first use-case, and partially discuss the second 
and third.
uRDTs have been proposed as a tool to detect malaria 
infections even at low-density infections (below 100–200 
parasites/µL), thus triggering their treatment in order to 
interrupt transmission in areas aiming for elimination, 
through mass test and treat (MTAT) campaigns, or pro-
active or reactive testing and treating. MTAT strategies 
evaluated throughout Africa and Asia have to date shown 
not to have a strong impact on malaria transmission 
when using cRDTs [23, 48–52], and consequently, the 
WHO does not recommend it as a tool to reduce trans-
mission [53]. However, it was argued that the impact 
of MTAT could be different if conducted using a highly 
sensitive RDT. Nevertheless, the field-based sensitivity of 
the uRDTs reported here and in other studies is similar 
to that of cRDTs, and mathematical modeling suggests 
that with the current uRDT performance, an impact 
on transmission with MTAT would only be observed if 
> 85% of the target population is treated [24]. This is a 
very high effective coverage that is rarely achieved in the 
community [54], and is arguably cost-effective. Addition-
ally, other more cost-effective interventions such as mass 
drug administration (MDA) have already shown to have a 
strong impact on transmission in endemic areas [35, 55–
57] irrespective of subpatent infection detection in the 
community. However, MDAs do not lead to the full inter-
ruption of malaria transmission [35] and strategies to 
target the remaining foci of transmission are still unclear. 
Highly sensitive RDTs have also been proposed to have a 
role in reactive strategies. Nevertheless, evidence against 
this option has already emerged from Cambodia where 
uRDTs failed to show significant improvement in diag-
nostic performance over cRDTs when used for active 
case detection, and other studies evaluating this question 
in other areas may be needed [26].
This study showed that the sensitivity of both RDTs 
significantly dropped among individuals older than 
15  years-old, particularly for cRDTs (39.2) compared to 
uRDTs (54.9) due to the high prevalence of lower density 
infections in this age group likely as a result of the cumu-
lative malaria exposure [58]. Moreover, circulating host 
antibodies against HRP2 could have interfered with HRP2 
detection by both RDTs and contributed to performance 
differences by age group [59, 60]. This points out a poten-
tial utility of uRDTs to detect infections among the semi-
immune adult population in the community, although in 
absolute terms this translated into 8 additional infections 
detected by the uRDTs among participating adults. Nev-
ertheless, this finding has not been consistently observed, 
as a similar study conducted in The Gambia reported a 
lower sensitivity of the same uRDT among individuals 
older than 10 (< 43.7%) compared to the sensitivity pre-
sented here. They also reported that the uRDT sensi-
tivity was lowest in children < 5  years old, although the 
study did not measure parasite densities or HRP2 levels 
[24]. In any case, the question remains as to whether the 
detection of subpatent infections is required to ultimately 
interrupt transmission in a malaria endemic area.
uRDTs have also been proposed to improve malaria 
case management at the health facility level [27]. This 
study revealed that the sensitivity of both RDTs increased 
among febrile individuals, to 84.9 for uRDTs and 79.2 
for cRDTs. This indicates that febrile cases which usu-
ally suffer from higher density infections as shown in 
this study (GMPD of 346.3 parasites/µL), are likely to be 
rightly diagnosed with both types of RDTs in southern 
Mozambique [32]. Therefore, this suggests that uRDTs do 
not provide added benefits to the detection of infections 
Table 5 Presence of  HRP2, pLDH-Pan, and  pLDH-Pf antigen by  type of  result from  RT-qPCR, cRDT and  uRDT in  233 
samples
TP True positive, FP false positive, TN true negative, FN false negative, HRP2 histidine-rich protein 2, pLDH Plasmodium lactate dehydrogenase, pLDH-Pan pan specific 
pLDH, pLDH-Pf P. falciparum specific pLDH
HRP2 positive pLDH‑Pan positive pLDH‑Pf positive
N = 160/223 N = 114/223 N = 97/223
n (%) n (%) n (%)
RT-qPCR positive
N = 134/223
cRDT positive = TP N = 71 71 (100.0) 56 (78.9) 56 (78.9)
cRDT negative = FN N = 63 46 (73.0) 38 (60.3) 33 (52.4)
uRDT positive = TP N = 80 79 (98.8) 61 (76.3) 59 (73.8)
uRDT negative = FN N = 54 38 (70.4) 33 (61.1) 30 (55.6)
RT-qPCR negative
N = 89/223
cRDT positive = FP N = 32 27 (84.4) 11 (34.4) 8 (25.0)
cRDT negative = TN N = 57 16 (28.1) 9 (15.8) 0 (0)
uRDT positive = FP N = 41 33 (80.5) 12 (29.3) 8 (19.5)
uRDT negative = TN N = 48 10 (20.8) 8 (16.7) 0 (0)
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among febrile individuals in the community when com-
pared to regular RDTs, a finding that has been similarly 
observed among febrile outpatients in Tanzania [27]. 
Similarly, studies conducted among pregnant women 
observed a higher performance of uRDTs among afebrile 
women compared to febrile ones [28, 30]. These studies 
were conducted under laboratory conditions using ret-
rospectively collected samples [28–30]. However, there 
is currently no evidence of the performance of uRDTs 
among pregnant women when the tests are directly con-
ducted at point of care. Acknowledging that this study 
was not powered nor designed to answer this question, 
it is worth noting that among the two afebrile infections 
detected by RT-qPCR in pregnant women, cRDTs and 
uRDTs only detected the high-density infection, but not 
the low-density one, despite the presence of HRP2 in 
both samples.
One of the commonly reported concerns of using a 
more sensitive HRP2-based RDT is that it may provide 
a higher number of FP in post-treated individuals, due 
to its capacity to detect remaining concentrations of 
HRP2 in the blood for a longer period of time [27]. This 
is the first report of the application of an antigenic ELISA 
applied to dried blood spots collected directly from the 
field. Using this technique, more than 80% of FP sam-
ples were HRP2-positive, but uRDTs did not detect a 
significantly larger number of FP results as a product of 
the increasing level of HRP2 detection of the test. The 
fact that there were ~ 20% of HRP2-negative samples 
that were falsely positive by cRDT or uRDT could be 
explained by the limit of HRP2 detection of the ELISA 
technique used. While the limit of detection on whole 
blood pellets is significantly lower than that of the uRDT 
[61, 62], the performance of the ELISA on DBS is likely 
to be lower depending on the efficiency of antigen recov-
ery and the antigen stability on the DBS (Jang et  al. 
2020; pers. commun,). Consequently, the uRDT may 
have detected true HRP2 positive cases with low HRP2 
concentration that were missed by the ELISA. With the 
advent of novel highly sensitive malaria antigen assays, 
understanding their performance in low parasite den-
sity specimens will be critical to accurately interpret its 
results in sub-microscopic infections [63, 64].
This study is subject to several limitations. First, the 
diagnostic performance analysis was conducted using 
RT-qPCR as the gold standard. In the younger age 
groups, the proportion of positive RT-qPCR samples 
was very similar or even lower to the proportion of posi-
tive uRDT samples. This can be partly explained by the 
high number of FP samples that were HRP2-positive 
in younger age groups. Children may be more likely to 
remain RDT positive for a longer time after anti-malarial 
treatment than adults, as a result of less acquired immu-
nity and higher parasite densities leading to higher HRP2 
circulating concentrations [6, 59]. However, it is also 
possible that the level of detection of the RT-qPCRs used 
in this study may have missed some infections. This may 
have been the case given that the sensitivity and specific-
ity of uRDT reported here are slightly higher than those 
reported in other malaria endemic areas [23–26]. Simi-
larly, the presence of pLDH antigens among RT-qPCR 
negative samples indicate that some of these samples 
may have been positive, although these results may 
also be explained by the limitations of the ELISA assay 
for this antigen as mentioned above. Additionally, RDT 
results could have also been affected by factors such as 
the prozone effect, which could have been the cause of 
high-density infections not detected by either RDT [11]. 
In spite of intense training, field workers not follow-
ing standard procedures (e.g. not collecting the right 
amount of blood, not placing the right amount of rea-
gent, not waiting for a sufficiently long period of time) or 
even data entry errors may have compromised the qual-
ity of these results [65].
Conclusion
Overall, these results contributed to the growing evi-
dence from field-based studies that show that the Abbott 
Pf malaria uRDTs do not substantially outperform SD-
Bioline Pf malaria RDTs in the community or among 
febrile cases, and are still not comparable to molecular 
methods like RT-qPCRs. Therefore, the use-cases for 
the currently available uRDTs should be reviewed before 
malaria endemic countries with a long experience using 
the standard RDTs decide to switch to a different yet sim-
ilarly performing test.
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